Communication and stakeholders

Providing clear, accurate information about medicines to our audiences and stakeholders – patients, healthcare professionals, researchers, academics, industry representatives and the general public – is a key aspect of EMA’s public health mission. We work closely with our regulatory partners and stakeholders both within the EU and globally. We also use many different channels to disseminate this information: we contribute articles to relevant scientific journals, we maintain regular communication with media and we engage with diverse audiences across different social media platforms.

External communication

In 2025, EMA issued 119 press releases and news items to keep its audiences across the EU and beyond informed about key developments in the assessment of medicines and major achievements in both new and ongoing initiatives. EMA organised one press briefing on the human medicines highlights of 2024. In addition, EMA launched a new podcast, ‘Inside EMA’, targeted at science enthusiasts, which showcases the science and the people behind medicines regulation; the first two episodes were published in 2025.

In its efforts to inform the public about new medicines or new uses of authorised medicines, EMA published 195 medicines overviews. It also communicated on safety concerns arising for some medicines through 13 public health communications. To keep the public and healthcare professionals up to date about specific actions required for some medicines, 18 direct healthcare professional communications and 16 shortage catalogue entries were also published.

The EMA website remains the primary communication platform, offering a thorough source of information and guidance on centrally authorised medicines and EU medicine regulation. In 2025, 3,382 webpages were added and updated, and 8,882 documents were published on the site. Additionally, EMA’s social media presence kept expanding through experimenting with different tools to engage new audiences. In 2025, EMA conducted its first social media campaign working with content creators: the #HealthNotHype campaign aimed to raise awareness about the safe and responsible use of GLP-1 receptor agonists. By the end of the year, 479 posts and 52 videos were shared across social media platforms. Two LinkedIn live events were organised, one in June on ‘Strengthening evidence generation in the EU’ and the second in September, on the topic ‘Smarter trials, stronger Europe. New targets for clinical research’. EMA staff and experts contributed 127 articles on scientific and regulatory subjects to international journals. Ninety per cent of all articles are publicly available under an open access licence.

Requests for information and access to documents

Providing citizens with clear, transparent information about its activities is a fundamental aspect of EMA’s work. In 2025, the Agency received 6,636 requests for information. EU citizens have the right to access documents held by EU institutions, bodies, offices and agencies. EMA facilitates this access in accordance with the principles and conditions outlined in Regulation (EC) No 1049/2001 and the Agency’s policy on document access. In 2025, EMA received 732 requests for access to documents (representing over 1,300 documents), with most of these requests originating from the pharmaceutical industry, followed by academia/research institutes.

Publication of clinical data

EMA releases clinical data provided by pharmaceutical companies to support their regulatory submissions for human medicines under the centralised procedure. This follows the Agency’s flagship policy on the publication of clinical data. In 2025, and following the completion of step 2 of the relaunch of Clinical Data Publication, 5,370 clinical data documents were published from 92 different procedures, which is in line with 2024. The publication of clinical data for non-COVID medicines containing new active substances resumed in 2023, following its interruption at the end of 2018 because of the business continuity measures introduced for the Agency’s relocation to the Netherlands and subsequently due to the COVID-19 pandemic. This led to an increase in the usage of the clinical data website in 2024, which then stabilised in 2025.